학술논문
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Document Type
Article
Author
Source
In The Lancet HIV March 2020 7(3):e164-e172
Subject
Language
ISSN
2352-3018